Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype. The patients will be treated in two therapy groups: Experimental arm A: Chemotherapy with FOLFOXIRI + Cetuximab Standard arm B: Chemotherapy with FOLFOX + Cetuximab
创建时间：
2018-01-15
